Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Celldex Therapeutics Inc.

www.celldextherapeutics.com

Latest From Celldex Therapeutics Inc.

Bookmark
  • News

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

By John Davis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Research & Development
Bookmark
  • News

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

By John Davis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
Bookmark
  • News

Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

By Emily Hayes

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

Companies Research & Development
Bookmark
  • News

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

By Mandy Jackson

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Virus Research Institute Inc.
  • T Cell Sciences
  • Avant Immunotherapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celldex Therapeutics Inc.
  • Senior Management
  • Anthony S Marucci, Pres. & CEO
    Sam Martin, SVP, CFO
    Tibor Keler, PhD, EVP, CSO
    Ronald A Pepin, PhD, SVP, CBO
    Richard Wright, Chief Commercial Officer
    Diane C Young, MD, SVP, CMO
  • Contact Info
  • Celldex Therapeutics Inc.
    Phone: (908) 454-7120
    53 Frontage Rd.
    Ste. 220
    Hampton, NJ 08827
    USA
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By